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RNA sequencing and proteomics
approaches reveal novel deficits in the
cortex of Mecp2-deficient mice, a model for
Rett syndrome
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Scott A. Shaffer4, Daniel L. Flint5 and Michelle L. Olsen1,6*
Abstract
Background: Rett syndrome (RTT) is an X-linked neurodevelopmental disorder caused by mutations in the
transcriptional regulator MeCP2. Much of our understanding of MeCP2 function is derived from transcriptomic
studies with the general assumption that alterations in the transcriptome correlate with proteomic changes.
Advances in mass spectrometry-based proteomics have facilitated recent interest in the examination of global
protein expression to better understand the biology between transcriptional and translational regulation.
Methods: We therefore performed the first comprehensive transcriptome-proteome comparison in a RTT mouse
model to elucidate RTT pathophysiology, identify potential therapeutic targets, and further our understanding of
MeCP2 function. The whole cortex of wild-type and symptomatic RTT male littermates (n = 4 per genotype) were
analyzed using RNA-sequencing and data-independent acquisition liquid chromatography tandem mass spectrometry.
Ingenuity® Pathway Analysis was used to identify significantly affected pathways in the transcriptomic and proteomic
data sets.
Results: Our results indicate these two “omics” data sets supplement one another. In addition to confirming previous
works regarding mRNA expression in Mecp2-deficient animals, the current study identified hundreds of novel protein
targets. Several selected protein targets were validated by Western blot analysis. These data indicate RNA metabolism,
proteostasis, monoamine metabolism, and cholesterol synthesis are disrupted in the RTT proteome. Hits common to
both data sets indicate disrupted cellular metabolism, calcium signaling, protein stability, DNA binding, and cytoskeletal
cell structure. Finally, in addition to confirming disrupted pathways and identifying novel hits in neuronal structure and
synaptic transmission, our data indicate aberrant myelination, inflammation, and vascular disruption. Intriguingly, there
is no evidence of reactive gliosis, but instead, gene, protein, and pathway analysis suggest astrocytic maturation and
morphological deficits.
Conclusions: This comparative omics analysis supports previous works indicating widespread CNS dysfunction and
may serve as a valuable resource for those interested in cellular dysfunction in RTT.
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Background
Rett syndrome (RTT) is an X-linked neurodevelopmen-
tal disorder that annually affects 1:10,000–15,000
females worldwide. RTT is characterized by apparently
normal development until approximately 6–18 months
of age, when patients exhibit a decrease in motor and
cognitive functions [1]. Additional clinical features of
RTT patients include hand stereotypies, breathing ab-
normalities, gastrointestinal dysfunction, and seizures
[1]. RTT patients require life-long, constant care limited
to palliative procedures.
Approximately 95% of RTT patients have a mutation
in the transcriptional regulator methyl-CpG-binding
protein 2 (MECP2) gene [2, 3]. MeCP2 is a global
transcription factor that can activate and repress tran-
scription [4, 5], with additional roles in RNA splicing and
chromatin compaction [6–9]. While MeCP2 is expressed
in multiple tissues throughout the body, it is most highly
expressed in the brain, specifically in the cortex and
cerebellum [10, 11]. MeCP2 is most highly expressed in
post-mitotic neurons compared to other CNS cell types
[12, 13], with recent work indicating MeCP2 expression in
other neural cell populations including astrocytes, micro-
glia, and oligodendrocytes [14–18].
To elucidate the pathophysiology of RTT and identify
potential therapeutic targets, multiple laboratories have
investigated gene expression profiles in Mecp2-deficient
mice, rat, and postmortem human tissue utilizing
microarray as well as RNA sequencing (RNA-Seq) [4, 9,
19–34]. Collectively, these studies found significantly
altered gene transcription, in some instances hundreds of
genes, and provided valuable insight regarding additional
transcriptional roles of MeCP2 for miRNA and long
non-coding RNA [27–29, 35]. In addition to global
gene expression studies, few groups have examined
global protein expression changes in a RTT mouse
[36] and zebrafish [37] model, as well as RTT
patients [38, 39]. With recent advances in the sensi-
tivity that can be obtained from mass spectrometry-
based proteomics, there is an increasing need to
incorporate multi-omics approaches in understanding
the relationship between gene and protein expression
in various disease pathologies.
Accordingly, we postulated that examination of global
protein expression in RTT as well as a simultaneous
comparison in data obtained between two omics plat-
forms from the same animal model and tissue region
may elucidate unknown RTT pathophysiology. In the
present study, RNA-Seq, proteomics, and comparison of
our data to publicly available databases of cellular brain
gene expression patterns were applied to better
understand RTT pathophysiology. We performed these
studies in cortical tissue obtained from the Jaenisch
murine model of RTT, a commonly used model that
recapitulates many aspects of RTT pathophysiology,
including hind limb clasping, decreased mobility, breath-
ing abnormalities, abnormal gait, and seizures [40, 41].
Our data support recent works indicating widespread
cellular dysfunction in RTT and point toward novel
molecular targets in cellular metabolism, protein stability,
cytoskeletal structure, and calcium signaling.
Methods
Animals
All experimental protocols were followed according to
NIH guidelines and approval from the Animal Care and
Use Committee of the University of Alabama at
Birmingham. Wild-type (WT) males were bred with het-
erozygous Mecp2tm1.1Jae/+ (Jaenisch) female mice [40].
The founding heterozygous Mecp2tm1.1Jae/+ female mice
and WT male mice (C57BL/6J) were obtained from the
Mutant Mouse Resource and Research Centers
(MMRRC). Colonies were occasionally refreshed with
WT male mice from Charles River Laboratories (C57BL/
6NCrl) for breeding with Mecp2tm1.1Jae/+ female mice.
Genotypes of the resulting offspring were validated by
PCR of DNA collected from tail clips. Mutant male mice
(Mecp2Jae/y) along with their WT littermates were
collected after postnatal day 60 (P60+), which represents
the time point when Mecp2-deficient males are con-
sidered to be “symptomatic.” We define symptomatic
as exhibiting hind limb clasping upon suspension
from tail and decreased mobility [40], both of which
were observed in all Mecp2-deficient males at the
time of collection. For both RNA sequencing and
proteomics experiments (methods outlined below), an
n of 4 biological replicates per genotype were used,
with WT littermate animals used as controls. The
number of biological replicates was chosen based on
a previous study examining the relationship between
the number of biological replicates, RNA-sequencing
depth, and statistical power [42].
RNA and protein isolation
Animals were anesthetized under CO2 followed by rapid
decapitation. Whole brains were dissected in ice-cold
phosphate-buffered saline and then separated into the
cerebellum, brain stem, midbrain, and hippocampus.
One hemisphere of the whole cortex was dedicated for
RNA and the other for protein isolation. RNA was iso-
lated by placing the cortical hemisphere dedicated for
RNA in 1 mL of RNAlater™ solution (Invitrogen/Thermo
Fisher Scientific) and allowed to react at 4 °C for at least
1 week. RNA was collected using the Invitrogen™
Ambion™ PureLink™ RNA Mini Kit (Fisher Scientific)
according to the manufacturer’s instructions, with the fol-
lowing modifications: (1) tissue was homogenized in 1 mL
lysis buffer with β-mercaptoethanol (Sigma-Aldrich) in a
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dounce homogenizer 5 times and rested on ice for 5 min,
followed by another 5 rounds of homogenization; (2) ap-
proximately 15 mg of the homogenate was removed and
brought up to a final volume of 600 μL in lysis buffer with
β-mercaptoethanol (Sigma-Aldrich), then re-homogenized
as described above. RNA was eluted in 30 μL of auto-
claved and filtered Mill-Q® water. Proteins were isolated
from the remaining cortical hemisphere in ice-cold lysis
buffer (100 mM Tris base, pH 7.5 at room temperature,
1% (w/v) SDS) with protease inhibitor cocktail and phos-
phatase inhibitor cocktail 3 (Sigma-Aldrich, product num-
bers P8340 and P0044, respectively) such that the final
concentration was 40 mg/mL. Lysates were sonicated
using the Model 120 Sonic Dismembrator (Fisher Scien-
tific) for 7 s at 70% amplitude, pulse 20 s, and rest 50 s for
2 cycles. Protein lysates were centrifuged to pellet debris.
The supernatant was removed into another tube and
quantified using a bicinchoninic acid (BCA) assay kit
(Pierce/Thermo Scientific).
RNA sequencing
RNA samples were submitted to the Genomics Core
Laboratory in the Heflin Center of Genomic Sciences at
the University of Alabama at Birmingham for sample
preparation and sequencing. The samples were first
DNase-treated and assessed for total RNA quality using
the Agilent 2100 Bioanalyzer, followed by 2 rounds of
polyadenylate positive (poly A+) selection and conver-
sion to cDNA. RNA sequencing was performed on the
Illumina HiSeq 2500 using the latest versions of sequen-
cing reagents and flow cells, providing up to 300 GB of
sequence information per flow cell. TruSeq library gen-
eration kits were used according to the manufacturer’s
instructions (Illumina). Library construction consisted of
random fragmentation of the poly A+ mRNA, followed
by cDNA production using random primers. The ends
of the cDNA were repaired, A-tailed, and adaptors li-
gated for indexing (up to 12 different barcodes per lane)
during the sequencing runs. The cDNA libraries were
quantitated using qPCR in a Roche LightCycler 480 with
the Kapa Biosystems kit for library quantitation (Kapa
Biosystems) prior to cluster generation. Clusters were
generated to yield approximately 725K–825K clusters/
mm2. Cluster density and quality were determined dur-
ing the run after the first base addition parameters were
assessed. Paired-end 2 × 50 bp sequencing runs were
performed to align the cDNA sequences to the reference
genome mouse mm10. Approximately 15 million paired
50 bp reads were obtained per sample.
RNA-Seq bioinformatics analysis
All RNA-Seq fastq reads (GEO Series accession number
GSE96684) were processed in the Galaxy platform [43].
First, raw RNA-Seq reads were concatenated using the
“Concatenate datasets tail-to-head” tool. The concatenated
raw fastq reads were then trimmed using Trim Galore!
(Galaxy version 0.4.2; [44]) to remove adapter sequences
and low-quality base pairs with the following parameters:
selected “paired-end” library; trimming reads—automatic
detection; trims 1 bp off every read from its 3′ end—yes;
no removal of N bp from 3′ end of reads 1 and 2 (respect-
ively); and all other settings left at default. Trimmed fastq
reads were then run through FastQC (Galaxy version 0.65;
[45]) for additional quality control measures. Following
quality control, the reads were aligned to the mouse
mm10 reference genome using TopHat (Galaxy version
2.1.0; [46, 47]) using the following parameters: mean inner
distance between mate pairs—175; standard deviation for
distance between mate pairs—20; report discordant pair
alignments—yes; and all other settings left at default.
Aligned reads were assembled using Cufflinks (Galaxy
version 0.0.7; [46, 48]) using the following parameters:
max intron length—300,000; min isoform fraction—0.1;
pre-mRNA fraction—0.15; perform quartile normaliza-
tion—yes; use reference annotation—use reference an-
notation, with the iGenomes UCSC mm10 genome
used as the reference annotation [49]; perform bias
correction—yes, reference sequence data—locally cached,
using reference genome—mouse mm10; use multi-read
correct—yes; and job resource parameters—left at default
values. Following transcript assembly and estimated frag-
ments per kilobase of transcript per million fragments
mapped (FPKM) abundances, each sample’s assembled
transcript was merged using the Cuffmerge (Galaxy ver-
sion 2.2.1.0; [46, 48]) tool with the following parameters:
use reference annotation—yes, reference annotation—i-
Genomes UCSC mm10 genome [49]; use sequence
data—no; minimum isoform fraction—0.05; and job
resources parameters—left at default. Finally, Cuffdiff
(Galaxy version 2.2.1.3; [46, 48]) was used to calculate
statistical changes in gene expression using the following
parameters: transcripts—output file from Cuffmerge step;
omit tabular data sets—no; generate SQLite—yes; input
data type—SAM/BAM; condition 1—WT TopHat ac-
cepted hits files; condition 2—Mecp2Jae/y TopHat accepted
hits files; library normalization method—quartile; disper-
sion estimation method—per-condition; false discovery
rate—0.05; minimum alignment count—100; use multi-
read correct—yes; perform bias correction—yes; reference
sequence data—locally cached, reference genome mouse
mm10; include read group data sets—yes; include count
based output files—yes; apply length correction—cufflinks
effective length correction; and all other remaining param-
eters were left at default settings. Since poly A+ selection
was utilized to generate the cDNA libraries used for RNA-
Seq, any significant and differentially expressed genes that
mapped to a putative non-coding gene were removed
from analysis.
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Proteomics
In-gel tryptic digest
An amount corresponding to 40 μg of protein based on
a BCA assay with BSA as a reference standard (Pierce,
Rockford, IL) was processed by SDS-PAGE using a
4–20% polyacrylamide gel (Bio-Rad, Hercules, CA). The
gel was run for 5 min at 120 V and stained with Coo-
massie Brilliant Blue R-250 protein stain comprised of
0.05% Coomassie Brilliant Blue R-250 (w/v)/50% metha-
nol (v/v)/10% acetic acid (v/v) for 30 min at room
temperature. The mobility region was excised into
1-mm cubes and destained overnight in 15% methanol
(v/v)/10% glacial acetic acid (v/v). On the next day, the
gel slices were destained for an additional 4 h until the
stain was completely removed. The gel cubes were re-
duced with 10 mM dithiothreitol at 60 °C for 30 min
followed by alkylation with 50 mM iodoacetamide at
room temperature for 30 min. The reducing and alkylat-
ing buffers were removed, and the gel cubes were placed
into acetonitrile and allowed to evaporate to dryness at
room temperature. Trypsin gold (Promega, Madison,
WI) in 100 mM ammonium bicarbonate was added to
each sample at a 1:20 trypsin to total protein ratio and
allowed to digest at 37 °C for 16 h. The digests were
aliquoted into fresh tubes, and extraction buffer consist-
ing of 50% acetonitrile (v/v)/5% formic acid (v/v) was
added and left at room temperature for 2 h and then
combined with each sample’s overnight trypsin digest.
Samples were vacuum centrifuged to dryness, resus-
pended in 0.1% formic acid (v/v), and BCA assayed with
undigested BSA as a reference to determine peptide total
concentrations.
Data-independent acquisition LC-MS/MS
In each liquid chromatography mass spectrometry (LC-
MS/MS) injection, 1 μg of peptides was separated on a
NanoAcquity UPLC (Waters, Milford, MA). A 3-μL in-
jection was loaded in 5% acetonitrile (v/v)/0.1% formic
acid (v/v) at a 4 μL/min flowrate for 4 min onto a 100-
μm I.D. fused-silica pre-column packed with 2 cm of
5 μm (200 Å) Magic C18AQ (Bruker-Michrom, Auburn,
CA) and eluted using a flowrate of 300 nL/min onto a
75-μm-inner-diameter analytical column packed with
25 cm of 3 μm (100 Å) Magic C18AQ particles to a
gravity-pulled tip. A linear gradient was applied to elute
peptides from 100% solvent A consisting of 0.1% formic
acid (v/v) to 35% solvent B comprised of acetonitrile
containing 0.1% formic acid (v/v) in 90 min. Ions were
introduced by positive electrospray ionization via liquid
junction into a Q-Exactive hybrid mass spectrometer
(Thermo, Waltham, MA) operating in data-independent
acquisition (DIA) mode. A total of 6 injections were per-
formed to analyze each sample corresponding to the
precursor m/z ranges 501–552, 553.5–604.5, 606–657,
658.5–709.5, 711–762, and 763.5–814.5 using a modified
application of the precursor acquisition independent
from ion count (PAcIFIC) approach [50]. The sequential
inclusion list for each precursor m/z range included 35
precursor m/z centers and stepped 1.5 m/z per inclusion
list center to provide an overlap of 1 m/z between each
inclusion list precursor m/z range assayed. Centroid
MS/MS data were acquired at 17,500 FWHM resolution
with an AGC target value of 2e5, a maximum IT fill time
of 80 ms, an isolation width of 2.5 m/z, a fixed first mass
of 140 m/z, normalized collision energy of 27, and
default charge state of 2.
Proteomics data analysis
Protalizer version 2.1 (Vulcan Analytical, Birmingham,
AL) was used to automate the analysis of DIA data and
combine the results from the 6 injections per sample
(ProteomeXchange Consortium/PRIDE partner reposi-
tory [51, 52] data set identifier PXD006460). Peptides
and source proteins were identified by an X! Tandem
Sledgehammer MS/MS database search following decon-
volution of MS/MS spectra as previously described by
retaining fragment ions within 70% of the maximum
intensity of each fragment ion when compared across se-
quential MS/MS scans using a 0.01 m/z tolerance [53].
The mouse Swiss-Prot reference proteome was used for
all searches that was downloaded on March 17, 2015,
and contained 6704 sequences (not including reversed
sequence decoys used to determine the false discovery
rate). A precursor tolerance of 2.5 m/z and fragment tol-
erance of 20 ppm were applied with a maximum of 2
missed cleavages and false protein discovery rate of 1%.
Potential modifications included in each search were
oxidation of M residues, pyro-glutamic acid at N-
terminal E and Q residues, N-terminal acetylation, and
phosphorylation at S, T, and Y sites. Carbamidomethyla-
tion of C residues was searched as a fixed modification.
Peptides assigned to different proteins in separate files
were assigned to a single top match determined by the
protein entry most often assigned by X! Tandem.
Relative quantification of peptides was performed by
MS2 area-under the-curve (AUC) chromatogram inten-
sities using a minimum of 5 and maximum of 9 b/y
fragment ions in either a +1 or +2 charge state with in-
tensities at least 10% of the strongest fragment ion
assigned to each peptide in MS/MS spectra. Peptides
not consistently detected in each file that were acquired
with the same PAcIFIC assay were extracted in the files
they were not detected using normalized retention time
as described elsewhere [53]. The intensities of peptide
MS2 chromatograms were normalized by up to 25 pep-
tides quantified in each sample that had the least
amount of intensity variation and the most similar reten-
tion time to correct for retention time-dependent matrix
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effects [53]. The normalized MS2 chromatograms for
each peptide were then placed in a relative scale with 1
being the smallest amount detected.
To calculate protein-level relative abundance across
the Mecp2Jae/y and WT mice, each peptide assigned to a
protein that was detected in every file compared was
used for quantification. Proteins lacking at least one
peptide detected in every sample were quantified with
all the peptides that had MS2 chromatograms detected
in any file. The median relative abundance of multiple
peptides used for protein-level quantification was
applied to determine the overall relative protein abun-
dance of the Mecp2Jae/y mice versus WT. Statistical
significance of protein-level differences was determined
using an unpaired t-test for all the peptides used to
quantify each protein using a p-value cutoff of p < 0.1 as
previously applied [54].
Western blotting
Lysates were boiled in 2× sample loading buffer
(100 mM Tris base, pH 6.8, 4% SDS in Laemmli-sodium
dodecyl sulfate, 600 mM β-mercaptoethanol, 200 mM
dithiothreitol (DTT), and 20% glycerol) in a 1:1 ratio for
15 min at 60 °C. A final concentration of 10 μg per sam-
ple was loaded into a 4–20% gradient pre-cast mini-
PROTEAN® TGX™ gel (Bio-Rad) and ran at 200 V in 1×
running buffer (24.76 mM Tris base, 190 mM glycine,
0.1% SDS).
For blots tested for RNPEP, QDPR, and CIRBP protein
expression, gels were transferred to a nitrocellulose
membrane using the Trans-blot turbo system (Bio-Rad),
mixed molecular weight protocol (2.5 A, 25 V for
7 min), followed by blocking with LI-COR® blocking buf-
fer at a 1:1 ratio with TBS. The blots were incubated
with primary polyclonal chicken anti-GAPDH (EMD
Millipore) at 1:2500 for 15 min at room temperature,
while the remaining primary antibodies were incubated
overnight at 4 °C: polyclonal rabbit anti-RNPEP (Pro-
teintech) at 1:1000, polyclonal rabbit anti-QDPR (Pro-
teintech) at 1:1000, and polyclonal rabbit anti-CIRBP
(Proteintech). All secondary antibodies were either goat
anti-rabbit or goat anti-chicken (LI-COR®), all incubated
at 1:10,000 for 1 h at room temperature. Imaging was
performed on a LI-COR® Odyssey machine with 1 or
1.5 intensity on both the 680 and 800 channels. All
rabbit antibodies were imaged in the 680 channels
and chicken in 800.
For blots tested for MeCP2, NEFM, mGluR3, and
HSPH1 protein expression, the gels were transferred to
an Immobilon-P PVDF membrane (EMD Millipore) for
1 h at 100 V in 1× transfer buffer (250.7 mM Tris base,
190 mM glycine, 20% methanol) with an ice pack at
room temperature, followed by blocking with 10% non-
fat dry milk/0.1% Tween-20/TBS (10% milk-TBST) for
1 h at room temperature. The blots were initially incu-
bated with primary antibody chicken anti-GAPDH at
1:2000 (EMD Millipore) for 1 h at room temperature,
washed 3 times in 10% milk-TBST, and incubated for
1 h at room temperature with secondary antibody goat
anti-chicken at 1:2000 (Santa Cruz Biotechnology). Blots
were then washed 3 times with 10% milk-TBST and im-
aged with Classico chemiluminescent reagent (EMD
Millipore) using an autoradiography film developing
system (Denville Scientific). The blots were then indi-
vidually probed with the following antibodies and condi-
tions: mouse anti-MeCP2 at 1:2000 (Sigma) for 2 h at
room temperature, rabbit anti-NEFM at 1:1000 (Protein-
tech) for 2 h at room temperature, rabbit anti-mGluR3
at 1:500 (Alomone labs) overnight at 4 °C, and rabbit
anti-HSPH1 at 1:150 (Novus Biologicals) overnight at 4 °C.
The respective secondary antibodies were incubated with
blots at 1:2000 for 1 h at room temperature: goat anti-
mouse (Santa Cruz) and goat anti-rabbit (Santa Cruz).
Protein quantification for all blots was performed using
Image Studio Lite (LI-COR®) and Origin2015 (OriginLab).
Relative protein amounts per antibody tested were normal-
ized to GAPDH expression in the same lane.
Pathway analysis
Ingenuity® Pathway Analysis (IPA®; Qiagen) was used to
identify significant biological pathways in both RNA-Seq
and proteomics data sets. A list of detected genes and
detected proteins (including post-translational modifica-
tions) was used as the data input for both individual and
comparison pathway analyses, using a q < 0.05 cutoff for
the gene pathway and p < 0.1 cutoff for the protein path-
way analyses [54] such that only significant genes/pro-
teins were considered for significant pathways. The
“User dataset” option was chosen to use each individual
detected gene/protein data set as the “reference set” for
which to generate significant pathways. Pathways from
the “diseases and biological functions” category were
used for comparison analyses. Fisher’s t-test of p < 0.05
(or −Log10 p-value > 1.3) was used to determine statis-
tical significance of a pathway.
Results
Global gene expression in symptomatic Mecp2Jae/y whole
cortex
We began our studies by performing RNA-Seq in whole
cortical tissue obtained from the Mecp2Jae/y murine
model of RTT. Previous studies have analyzed the tran-
scriptome of RTT mice; however, analysis performed in
the same affected brain region in the same animal model
allowed us to make general comparisons across RNA-
Seq and proteomics platforms. While each data set offers
unique insight into the disease, the comparison of the
two allows us to make general assumptions that (1)
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differentially expressed “hits” common to both platforms
possibly share a transcriptional mechanism of dysregula-
tion and (2) proteins differentially expressed without a
similar change in gene expression may indicate differ-
ences in either protein stability or posttranscriptional
regulation. We chose to analyze whole cortex (WCX) in
a Mecp2Jae/y murine model of RTT because MeCP2 pro-
tein is highly expressed in WCX [10, 11] and has patho-
logical characteristics of RTT [26]. RNA sequencing
(RNA-Seq) was used to quantify gene expression of 15
million paired 50 bp reads in WT and symptomatic
Mecp2Jae/y mice (as described in the “Methods” section).
We identified 391 significant, differentially expressed
(DE) genes (Fig. 1a, Additional file 1). Of these 391
genes, 132 genes had increased expression and 259 had
decreased expression. To assess the consistency of our
data with previously published microarray and RNA-Seq
studies of RTT, we compared our findings to
transcriptome-based data on different species and brain
regions [4, 19–26, 33, 34, 55, 56]. In our data, 35 genes
were identified as known RTT differentially expressed
genes and are represented in Fig. 1b and Table 1. Of the
35 genes, 18 were identified in supplemental material
from [4] and [34] (Table 1). Additionally, within the
group of 35 identified RTT hits, we found that 66% of
the DE genes had decreased expression, while 34% had
increased expression (Fig. 1b, Table 1). These observa-
tions are consistent with previous studies with the
exception of one gene Cacnb3. In our data set, Cacnb3
is significantly decreased; however, Tudor et al. found
that this same gene was upregulated [20].
We then focused on comparisons of our RNA-Seq
data to microarray studies also performed in Mecp2-de-
ficient cortex [20, 24]. We specifically focused on these
two studies for a number of reasons. First, studies have
shown brain tissue region and cell type-specific gene
and protein expression differences [30, 57–60]. While
we do not negate the importance of other transcriptomic
studies performed in the RTT field, we chose to compare
our data set to studies performed in the same MeCP2
Fig. 1 Transcriptome-wide expression in Mecp2Jae/y cortex. a. Heat map of 391 significant, differentially expressed (DE) genes. Each genotype has
4 biological replicates, where each column represents 1 biological replicate and each row represents the Log10-transformed FPKM of a significant DE
gene. Biological replicates are listed in the order of how they cluster, which is indicated by the cluster dendrogram above the heat map. Genes with a
false discovery rate (q-value or FDR) of < 0.05 were considered to be significantly, differentially expressed. b. Volcano plot of all the detected genes’
expression (Log2 fold change) in the Mecp2
Jae/y whole cortex transcriptome. Significant DE genes previously identified as RTT hits are highlighted in
red crosses and arrows. Due to space constraints, additional genes identified in supplemental material from Chahrour et al. [4] and Veeraragavan et al.
[34] were not highlighted in this volcano plot; for information on these genes, see Table 1. Dotted line indicates a q-value of 0.05, where anything
above the line indicates a significant DE gene. c. Venn diagram comparing our transcriptome data to previously published microarray studies
(Urdinguio et al. [24] and Tudor et al. [20]) on Mecp2Jae/y mouse cortex. Note that in the Urdinguio study, the fold change expression was not
differentiated between cortex, midbrain, and cerebellum due to their finding that there were no differences in gene expression between the 3 brain
regions [24]; rather, fold change values represent combined tissue expression. Six genes were shared between the Mecp2Jae/y transcriptome data and
the Urdinguio et al. study, while 5 genes from the Tudor et al. study were shared in common with the transcriptome data. One of the targets (Fabp7)
from the Tudor et al. study was also overlapped with the Urdinguio et al. study
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Table 1 Significant DE genes overlapping with previously identified RTT hits
Gene targets: this study UniProt: function keywords Fold change RTT gene hits: direction of
expression (with references)
Aacs* • Molecular function: ligase
• Biological process: fatty acid metabolism;
lipid metabolism
• Ligand: ATP-binding; nucleotide-binding
− 0.79 Decrease4
Aldh1a1* • Molecular function: oxidoreductase
• Ligand: NAD
− 0.67 Decrease4
Arhgdig • Molecular function: GTPase activation − 0.69 Decrease2
Auts2 N/A 1.40 Increase7
C1qa • Biological process: complement pathways;
immunity; innate immunity
− 0.76 Decrease7
Cacnb3 • Molecular function: calcium channel; ion
channel; voltage-gated channel
• Biological process: calcium transport;
ion transport; transport
• Ligand: calcium
− 0.79 Increase2
Calb1 • Ligand: calcium; metal-binding; vitamin D − 0.79 Decrease5
Calr* • Molecular function: chaperone
• Ligand: calcium; lectin; metal-binding
− 0.80 Decrease8
Dgkg* • Molecular function: kinase; transferase
• Ligand: ATP-binding; calcium; metal-binding;
nucleotide-binding; zinc
1.42 Increase4, 8
Ephx2* • Molecular function: hydrolase
• Biological process: aromatic hydrocarbons
catabolism; detoxification; lipid metabolism
• Ligand: magnesium; metal-binding
− 0.71 Decrease4
Fabp7 • Biological process: transport
• Ligand: lipid-binding
− 0.39 Decrease2,5
Fkbp5 • Molecular function: chaperone; isomerase;
rotamase
1.81 Increase3,4,5,7,8
Gabra3 • Molecular function: chloride channel; ion
channel; ligand-gated ion channel; receptor
• Biological process: ion transport; transport
• Ligand: chloride
− 0.81 Decrease6
Gfra1* • Molecular function: receptor 1.26 Increase4, 8
Grm3* • Molecular function: G-protein coupled
receptor; receptor; transducer
− 0.63 Decrease4
Hpcal4* • Ligand: calcium; metal-binding − 0.69 Decrease4, 8
Hsph1 • Biological process: stress response
• Ligand: ATP-binding; nucleotide-binding
− 0.80 Decrease3
Itm2a N/A − 0.73 Decrease5
Mecp2 • Molecular function: DNA-binding; repressor
• Biological process: transcription; transcription
regulation
− 0.66 Decrease1, 4
Msmo1/
Sc4mol
• Molecular function: oxidoreductase
• Biological process: lipid biosynthesis;
lipid metabolism; steroid biosynthesis;
steroid metabolism; steroid biosynthesis;
sterol metabolism
• Ligand: iron; NAD
− 0.77 Decrease5
Myo1b* • Molecular function: actin-binding;
calmodulin-binding; motor protein; myosin
• Ligand: ATP-binding; nucleotide-binding
1.32 Increase4, 8
Pcsk1 • Molecular function: hydrolase; protease;
serine protease
• Ligand: calcium
− 0.74 Decrease6
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animal model, tissue region, and time point. A RNA-Seq
study by Li et al. meets this criteria [9]; however, this
study only reported upregulated genes and utilized
different bioinformatics approaches. We found 175 up-
regulated genes in the Li et al. study were also present in
our data set. Of these, 84/175 genes were also signifi-
cantly upregulated in our data set (p < 0.05). We found
5 out of the 12 genes identified in the Tudor et al.
microarray study and 6 out of the 20 genes identified in
the Urdinguio et al. study were also significant DE genes
in our data set (Fig. 1c). A common statistical signifi-
cance threshold in RNA-sequencing studies is a q-value
less than 0.05, which is meant to reduce the number of
false positives observed, but may also underestimate bio-
logically relevant changes. Reducing the significance
threshold stringency to p < 0.05 in our data set, we iden-
tified an additional 2 genes from the Tudor et al. (7/12)
and 2 genes from the Urdinguio et al. (8/20) study. Our
RNA-Seq data correlates better with the individual
microarray studies than these two studies correlate to
each other, which is notable given strain differences
between each of the individual studies, and that the
Urdinguio et al. study utilized tissue pooled from three
brain regions from the Mecp2tm1.1Bird/y mouse model
Table 1 Significant DE genes overlapping with previously identified RTT hits (Continued)
Gene targets: this study UniProt: function keywords Fold change RTT gene hits: direction of
expression (with references)
Pdia4* • Molecular function: isomerase − 0.71 Decrease4, 8
Plagl1 • Ligand: metal-binding; zinc 1.37 Increase5
Prkcg* • Molecular function: kinase; serine/threonine-
protein kinase; transferase
• Biological process: biological rhythms
• Ligand: ATP-binding; calcium; metal-binding;
nucleotide-binding; zinc
− 0.82 Decrease8
Pvalb • Molecular function: muscle protein
• Ligand: calcium; metal-binding
1.27 Increase2
Pygm • Molecular function: glycosyltransferase;
transferase
• Biological process: carbohydrate metabolism;
glycogen metabolism
• Ligand: nucleotide-binding; pyridoxal phosphate
1.29 Increase6
Qdpr* • Molecular function: oxidoreductase
• Biological process: tetrahydrobiopterin biosynthesis
• Ligand: NADP
− 0.74 Decrease4
Rnpep* • Molecular function: aminopeptidase; hydrolase;
metalloprotease; protease
• Ligand: metal-binding; zinc
− 0.78 Decrease4
Sgk1 • Molecular function: kinase; serine/threonine-
protein kinase; transferase
• Biological process: apoptosis; stress response
• Ligand: ATP-binding; nucleotide-binding
1.37 Increase2,3
Slc24a4* • Biological process: antiport; calcium transport;
ion transport; olfaction; potassium transport;
sensory transduction; sodium transport;
symport; transport
• Ligand: calcium; potassium; sodium
1.58 Increase4
Slc9a3r1* • Biological process: Wnt signaling pathway − 0.74 Decrease8
Sun2* • Biological process: meiosis 1.42 Increase8
Ugp2* • Molecular function: nucleotidyltransferase;
transferase
• Ligand: magnesium; metal-binding
− 0.73 Decrease4
Zmat4* • Molecular function: DNA-binding
• Ligand: metal-binding; zinc
1.5 Increase8
First column represents the significant DE gene identified in this study, along with the UniProt function keyword(s) for each gene (second column) and the Log2
fold change expression of the gene in our data set (third column). DE genes with an asterisk (*) represent genes identified in supplemental material from
Chahrour et al. [4] and Veeraragavan et al. [34]. All function keywords were found from the UniProtKB/Swiss-Prot database [131] per respective DE gene. DE genes
without a published function keyword in the UniProtKB/Swiss-Prot database are represented as “N/A.” The last column represents the previously identified RTT
hits’ fold change expression direction, with each superscript representing that gene’s respective references. Superscript references are as follows: (1) Amir et al. [2],
(2) Tudor et al. [20], (3) Nuber et al. [21], (4) Chahrour et al. [4], (5) Urdinguio et al. [24], (6) Ben-Shachar et al. [25], (7) Lin et al. [33], and (8) Veeraragavan et al.
[34]. Rows in bold font represent previously identified RTT hits that were found to be specifically DE in the cortex
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[24]. These genes and their putative functions as well as
direction of expression levels for each hit are shown in
Table 1. We identified an additional 19 gene targets
previously found to be RTT gene hits in our data set that
had a p-value of less than 0.05, but did not meet the
false discovery rate, or FDR/q-value, cutoff of 0.05
(Additional file 2). Collectively, this suggests that our
data is in concordance with previous literature on
Mecp2-deficient mice.
In addition to known RTT hits, we also found a num-
ber of significant DE genes that have been previously
identified as autism spectrum disorder (ASD) candi-
date genes (q < 0.05). For example, mutations in
Auts2 [61, 62], Shank1–3 [63], and Foxp1 [64, 65]
have been found in various ASD patient cases. In our data
set, Auts2 and Foxp1 are significantly increased by 0.49
and 0.29 fold, respectively, while Shank1–3 are all de-
creased (Shank1: − 0.53 fold, Shank2: − 0.34 fold, Shank3:
− 0.37 fold) (Table 1, Additional file 1). The gene expres-
sion changes observed in our data are robust, as many
were identified across multiple models, different brain
regions, and numerous species. Importantly, this also pro-
vides validation in utilizing this data set as an appropriate
resource for comparing RNA-protein expression similar-
ities in the RTT model.
Recent work demonstrated that MeCP2 selectively re-
presses gene expression of long genes [30, 32]. These
two studies also showed long genes are enriched in
neurons and hypothesized that neuronal dysfunction in
RTT could be in part due to repression of long gene ex-
pression [30, 32]. Recent studies have also indicated that
disruption of long genes could also contribute to ASD
pathogenesis [66–68]. For example, one study has shown
that a heterozygous knockout of the autism candidate
gene Chd8 led to an increase in dysregulated long gene
expression [66], while another study found many ASD
candidate genes are long genes [67]. Interestingly, recent
studies have shown that topoisomerase inhibitors can
regulate the expression of long genes in different ASD
models [67, 68], suggesting that topoisomerase inhibitors
could serve as a potential therapeutic for autism. Col-
lectively, these studies highlight the need to understand
the relationship between long gene expression and ASD
and other ASD-related disorders such as RTT.
Given that MeCP2 is expressed in all CNS cell types,
we extended earlier studies exploring the relationship
between gene size and fold change expression within cell
type-specific DE genes in our data. Accordingly, we next
evaluated if the 391 identified significant DE genes in
symptomatic Mecp2Jae/y mice were enriched in a specific
CNS cell type using a publicly available database of
purified cortical CNS cell types [69]. The criteria for this
comparison were as follows: (1) a gene which demon-
strated a 3-fold or greater enrichment in 1 cell relative
to all others was considered cell type enriched and (2)
all other genes that varied less than 3-fold in any one
cell type were considered to be non-specific. Using these
criteria, 68% of the DE genes were not enriched in any
cell type (Fig. 2a, Additional file 3). The other 32% of DE
Fig. 2 Cell type-specific gene expression correlation. a. Mecp2Jae/y
cortex significant DE genes compared to top 500 CNS cell type-specific
genes based on the Zhang et al. study [69], which is also provided as a
public database. Each pie slice lists the number of DE genes associated
with each CNS cell type. b. Fold change expression and gene size
correlation in the Mecp2Jae/y transcriptome. Significant DE genes were
plotted by Log2 fold change (FC) expression (y-axis) and gene size (x-
axis; in units of kilobase (kb)) according to their respective CNS
cell type distribution (based on part A). Expression and gene size corre-
lations were also examined as a whole (bottom scatter plot in black). This
relationship is also represented to the right of each scatter plot based on
the number of short (defined as being less than 100 kb; gray) and long
(defined as being greater than 100 kb; turquoise) genes that are either
repressed (i.e., decreased expression) or activated (i.e., increased expres-
sion) in the Mecp2Jae/y cortex
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genes segregated into one enriched cell population. Of
the DE genes associated with a specific cell type, 31 were
enriched in neurons, 46 in astrocytes, 10 in microglia,
26 in oligodendrocytes (includes oligodendrocyte precur-
sor cells, newly formed oligodendrocytes, and myelinat-
ing oligodendrocytes), and 14 in endothelial cells
(Fig. 2a, Additional file 3). Additional comparisons to a
second CNS cell type-specific database [60] further
confirmed gene expression is disrupted across multiple
cell populations in the symptomatic RTT brain
(Additional file 4).
Based on the criteria outlined above, we cannot rule
out the possibility that a gene we termed “not enriched
in any cell type” is dysregulated in neurons. For example,
the gene Camk1 has strong associations with neuronal
transcription and synaptic activity. However, based on
our and the Zhang et al. criteria [69], Camk1 is catego-
rized as a “non-cell type enriched” gene. The non/cell
type-specific hits may be a direct result of MeCP2 defi-
ciency in neurons, MeCP2 deficiency in other CNS cell
populations, or alternatively are downstream of MeCP2
binding in one or multiple CNS populations. We also
cannot exclude the possibility that alterations observed
in gene and protein expression in non-neuronal cell
populations are due to the disease severity at the time
point these experiments were performed. However,
when we did a similar gene cell type-specific comparison
between Chahrour et al.'s study and Zhang et al.'s data-
base, we also observed a similar cell type-enriched distri-
bution as the data presented in our study (data not
shown), decreasing the possibility that our observed ex-
pression changes are due to disease severity.
We defined short genes as being less than 100 kb and
long genes as larger than 100 kb based on prior studies
[32] and calculated gene length based on the chromo-
somal location provided by the Cuffdiff differential gene
expression output file. We found 81% of the total list of
significant DE genes was short in our data (Fig. 2b,
Additional file 5). Of these short genes, 237 had de-
creased and 79 had increased gene expression. Similar to
previous work [30, 32], we found 71% (53/75) of the
long genes exhibit increased gene expression (Fig. 2b,
Additional file 5). Although the majority of genes in our
data set are short and repressed, the neuronal-enriched
DE genes in our data support previous studies showing a
bias for over-expressed long genes in neuronal popula-
tions [30] (Fig. 2b, Additional file 5). Additionally,
increased long gene expression was observed in
oligodendrocyte-enriched and non-cell type-specific DE
genes (Fig. 2b, Additional file 5). In contrast, the major-
ity of astrocyte-enriched DE genes showed decreased
gene expression, in which 92% (36/39) of short genes
and all 7 long genes exhibited decreased gene expression
(Fig. 2b, Additional file 5). Similar trends were observed
in endothelial-enriched DE genes, where 71% (10/14) of
the genes were short and decreased (Fig. 2b,
Additional file 5). Furthermore, within the microglial-
enriched DE gene group, all 10 genes are short and have
decreased gene expression (Fig. 2b, Additional file 5).
Together, these data provide an additional dimension
of cell type-specific gene expression changes in
Mecp2Jae/y animals.
Protein expression in symptomatic Mecp2Jae/y whole
cortex
To gain a more complete view of cellular and molecular
dysfunction in RTT, we examined global protein
abundance changes in symptomatic Mecp2Jae/y whole
cortex lysates using a DIA LC-MS/MS proteomics ap-
proach (see the “Methods” section; [50, 53]). We identi-
fied 465 significant protein changes out of 4789 total
quantified proteins. Of the 465 significant proteins, 299
proteins had increased fold changes in RTT mice while
166 had decreased fold changes compared to WT
(Fig. 3a, Additional file 6). To demonstrate the robust-
ness and sensitivity of the expression changes observed
in our proteomics data set, we performed Western blot
analysis on 3 top-ranking proteins based on large fold
change differences (fold change greater than ± 3;
MeCP2, CIRBP, RNPEP) along with 4 proteins with
smaller fold change differences (fold change less than ±
3; HSPH1, NEFM, QDPR, mGluR3) (Additional files 6
and 7). As expected, the MeCP2 protein was one of the
most highly decreased and significant proteins in the
data set and was also significantly decreased by Western
blot analysis (Additional files 6 and 7). Western blot
analysis also confirmed that the remaining 6 targets were
significantly different in the Mecp2-deficient cortex
(Additional file 7). Additionally, representative mass
spectrometry chromatograms confirmed qualitative
changes in peptides detected in WT versus Mecp2-defi-
cient cortical lysates (Additional file 7). Collectively,
these results lend support to the robustness and sensitiv-
ity of our proteomics data set.
We next examined whether any of the significant pro-
teins were previously identified RTT hits using the same
criteria as outlined in the RNA-Seq analysis section. Of
the 465 significant proteins, 37 were identified as previ-
ously published RTT targets, with the majority identified
from previous transcriptome studies (Fig. 3b, Add-
itional file 8). Three of the 37 hits (clusterin, Apo-J/Clu;
alpha-1-antitrypsin 1–1, AAT/Serpina1a; and apolipo-
protein A-I, Apo-AI/Apoa1; Fig. 3b, Additional file 8)
were identified from the limited proteomics studies pub-
lished in RTT [36–39] and have decreased expression.
Two significantly increased proteins in our data set
(transcriptional activator protein Pur-alpha, Purα/Pura,
↑1.19 fold; and core histone macro-H2A.2, mH2A2/
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H2afy2, ↑1.43 fold; Fig. 3b, Additional file 8) were previ-
ously identified as MeCP2 interacting proteins [4] as was
FK506-binding protein 51 (FKBP5; Additional file 8)
[21].
We identified several groups of differentially abundant
proteins that fall into broad categories that relate to
MeCP2 function, cellular dysfunction, and disease biol-
ogy (Tables 2 and 3). For instance, several proteins
related to RNA metabolism, including heterogeneous
nuclear riboproteins (hnRNP a0, hnRNP D0, hnRNP D-
like, hnRNP H2, hnRNP L), spliceosome components
(CD2BP2, CDC5L), and a transcriptional repressor
(mH2A2), were observed (Table 2). Each of these pro-
teins was significantly upregulated in RTT tissue relative
to WT. In particular, cold-inducible RNA-binding
protein (CIRBP), an RNA-binding protein upregulated in
response to hypoxia [70], shows one of the largest fold
increases in our data set (4.3-fold; Table 2). Interestingly,
this protein has previously been shown to be upregu-
lated in RTT tissue [21], although mRNA levels do not
appear to be affected ([71] and our data). Similar find-
ings were previously reported in RTT where multiple
synaptic proteins showed significant changes in protein
expression while no observed changes were found at the
transcript level [72]. These data suggest examining
global protein changes in RTT provide supplementary
information to transcriptomic studies.
Our proteome data indicate cellular dysfunction in RTT
may be facilitated by disrupted proteostasis (Table 2). We
observed significantly decreased abundance of multiple
heat shock proteins (HSPH1, HSP90α, HSP90β, and
HSPA4), including the small heat shock proteins alpha-
crystallin B chain (CRYAB) and HspB1 (Table 2). In sup-
port of these findings, a recent study has shown that
microglia isolated from pre-symptomatic RTT female
mice show decreased expression in heat shock genes [73].
Because of the important role that heat shock proteins
play in regulating protein folding and stability, it is
possible that expression changes in these heat shock pro-
teins could be influencing the protein expression changes
we observe in our proteomics data set. Furthermore, the
protein IMPACT, which mediates translation in response
to numerous cell stressors, was also upregulated in the
proteome data set (1.8-fold; Table 2). Elevated physio-
logical stress can also affect the protein expression levels
of FKBP5 (elevated in response to glucocorticoid signaling
[21]), the diacylglycerol-binding protein DGKγ, and the
guanine nucleotide exchange factor RasGRF1 [74, 75], all
of which are significantly increased in our data
(Additional file 6).
Fig. 3 Proteome-wide expression in Mecp2Jae/y cortex. a. Heat map of 460 significant, abundantly expressed proteins. Each column represents
pooled biological replicates per genotype (n = 4), and each row represents the relative abundance fold change of an individual protein (with or
without a PTM). Proteins with a p-value of < 0.1 were considered differentially abundant. b. Volcano plot of all the detected proteins’ expression
(Log2 fold change) in the Mecp2
Jae/y whole cortex proteome. Dotted line indicates a p-value of 0.1, where anything above the line indicates a
significant protein. Previously identified RTT hits are highlighted in red, blue, or purple filled circles. Red circles denote that the significant protein was
identified from a transcriptome-based gene expression study, blue circles denote identification from a proteomics-based study, and purple circles denote
identification from a non-omics-based study. Due to space constraints, only the selected RTT protein hits identified from proteomics and non-omics-based
studies were highlighted in this volcano plot. For a comprehensive list of all the identified RTT protein hits, refer to Additional file 8. c. Pie chart of significant
proteins compared to top 500 cell type-specific genes based on the Zhang et al. study [69]. All significant proteins were included in the analysis. Each pie
slice lists the number of significant proteins associated with each CNS cell type
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Recent reports indicate altered metabolism in RTT.
We observed significant expression of proteins involved
in ketone body metabolism and utilization (AACS) as
well as fatty acid oxidation (ACADVL) and glycogen me-
tabolism (UGP2) (Table 3). Lanosterol synthase (LSS), a
key enzyme in cholesterol synthesis, was elevated 8.1-
fold in our data set (Table 3). Cholesterol synthesis has
been shown to be disrupted in a suppressor screen in
Mecp2-deficient mice [76]. It is conceivable that elevated
LSS protein expression contributes to elevated choles-
terol triglycerides and LDLs commonly observed in RTT
patients [77, 78]. Our data also indicate altered
monoamine metabolism as evidenced by significant
downregulation of two key enzymes (QDPR, SPR) in-
volved in the production of dopamine, norepinephrine,
and serotonin (Table 3). The product of these enzymes
is tetrahydrobiopterin (BH4), an essential cofactor in the
production of amine neurotransmitters. Furthermore,
amine oxidase A (MAOA), which catalyzes the oxidative
deamination or degradation of these same neurotrans-
mitters, is upregulated in the proteome data set (Table 3).
Together, these findings provide additional support for
prior studies indicating that dopamine, norepinephrine,
and serotonin are downregulated in RTT mice and
patients [79, 80].
Finally, we identified a number of significantly altered
proteins associated with S-adenosylmethionine-
dependent methylation (GAMT, SPDSY, and MTHFD1L;
Table 3). This particular pathway converts methionine to
S-adenosylmethionine (SAM), whereby the methyl group
from SAM is transferred to different substrates such as
DNA [81, 82]. This finding is of interest to RTT because
Table 2 Differentially abundant proteins associated with RNA metabolism and proteostasis
Gene name Protein description FC p-value General putative function
RNA metabolism
H2afy2 Core histone macro-H2A.2 (mH2A2) 1.8 0.050 Gene repression
Cdc5l Cell division cycle 5-like protein 2.2 0.013 mRNA splicing
Cd2bp2 CD2 antigen cytoplasmic tail-binding protein 2 1.8 0.072 mRNA splicing
Hnrnpa0 Heterogeneous nuclear ribonucleoprotein (hnRNP) A0 2.0 0.076 RNA-binding protein
Hnrnpd Heterogeneous nuclear ribonucleoprotein (hnRNP) D0 1.4 0.029 RNA-binding protein
Hnrnpdl Heterogeneous nuclear ribonucleoprotein (hnRNP) D-like 2.1 0.024 RNA-binding protein
Hnrnph2 Heterogeneous nuclear ribonucleoprotein (hnRNP) H2 1.5 0.034 RNA-binding protein
Hnrnpl Heterogeneous nuclear ribonucleoprotein (hnRNP) L 1.8 0.077 RNA-binding protein
Cirbp Cold-inducible RNA-binding protein 4.3 0.047 RNA-binding protein
Ddx21 Nucleolar RNA helicase 2 2.9 0.009 rRNA transcription, processing, and
modification
Hp1bp3 Heterochromatin protein 1-binding protein 3 2.1 0.057 Transcription regulation
Proteostasis
Impact Protein IMPACT 1.8 0.002 Translational activation
Uchl5 Ubiquitin carboxyl-terminal hydrolase isozyme L5 1.6 0.037 Deubiquitylation
Adrm1 Proteasomal ubiquitin receptor ADRM1 3.0 0.007 Enhances Uchl5
Ublcp1 Ubiquitin-like domain-containing CTD phosphatase 1 3.5 0.068 Nuclear proteasome activity
Cryab Alpha-crystallin B chain −2.1 0.003 Chaperone-like activity
Hspb1 Heat shock protein beta-1 (HspB1) −1.7 0.020 Chaperone for protein folding
maintenance
Hsph1* Heat shock protein 105 kDa −2.1 0.004 Chaperone activity regulation
Hsp90aa1 Heat shock protein HSP 90-alpha (HSP90α) −1.5 0.058 ATP-dependent chaperone
Hsp90ab1 Heat shock protein HSP 90-beta (HSP90β) −1.4 0.056 ATP-dependent chaperone
Hspa4 Heat shock 70 kDa protein 4 −1.5 0.067 Molecular chaperone
Ahsa1 Activator of 90 kDa heat shock protein
ATPase homolog 1
−1.3 0.059 Chaperone binding
Significant proteins (p < 0.1) that are associated with either RNA metabolism (top half of table) or proteostasis (bottom half of table) are listed by gene name (first
column), followed by the full protein name (second column). For each protein, the fold change (“FC”) and p-value is provided (third and fourth columns, respectively),
along with a brief description regarding the putative function of that protein (“General Putative Function”). Information regarding the putative function of each protein
was obtained from the UniProtKB/Swiss-Prot database [131]. Gene names with an asterisk (“*”) indicates that the corresponding gene was also identified as significantly,
differentially expressed (DE) in the transcriptome by a q < 0.05. Bold proteins indicate that the respective protein has been previously identified as a RTT hit and/or
MeCP2 interacting protein (see text for references)
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MeCP2 binds methylated and un-methylated genomic
regions to regulate gene transcription [4], and global
MeCP2 methylation-binding patterns in RTT have been
well documented [13, 31, 32, 83, 84]. An additional
methyltransferase also had significant differential
abundance between RTT and WT animals (PRMT5;
Additional file 6). Methyl donor groups that are utilized
by SAM-dependent methylation mechanisms include
creatine, folate, folinic acid, and betaine, all of which
have also been implicated in RTT [85]. Collectively, this
suggests aberrant regulation of methyl donor group
availability to properly regulate DNA methylation, and
consequent downstream gene expression, in RTT.
Significant proteins in symptomatic Mecp2Jae/y whole
cortex are expressed in multiple CNS cell types
To determine if any of the significantly abundant pro-
teins identified in our proteomics data set were also
enriched in a specific cell type, we compared the 465
significant proteins to the same CNS cell type database
as the RNA-Seq data. Similar to our DE gene findings,
most significantly altered proteins were non-cell type
specific (Fig. 3c, Additional file 3). Of the cell type-speci-
fic significantly regulated proteins, 12 were neuronal-
enriched, 14 astrocyte-enriched, 4 microglial-enriched, 34
oligodendrocyte-enriched, and 10 endothelial-enriched
(Fig. 3c). Similar to the RNA-Seq data, the proteomics data
also suggest that loss of MeCP2 has downstream effects on
protein expression in different CNS cell populations.
It should be noted that in our study, we have solely ex-
amined gene/protein expression in whole cortical tissue
homogenate. A number of studies have identified this
“dilution effect” [30, 86, 87], where certain genes in one
cellular population could be masked by the gene expres-
sion from a heterogeneous cellular population. Addition-
ally, gene and proteins typically thought of as “cell type
specific” may lose their specificity in the RTT brain.
Future studies examining gene and protein expression
from multiple cell types simultaneously isolated from
the same RTT animal model and tissue region are
needed to properly address these potential confounds.
We also cannot exclude the possibility that changes in
gene and protein expression could be due to differences
in cell population number. Future studies utilizing
quantitative stereology and multi-channel immunohisto-
chemistry should be done to examine cell counts in WT
versus Mecp2-deficient brain tissue.
Transcriptome-proteome expression comparison
identifies novel hits
We next compared the proteome to the RNA-Seq data
set. Previous studies making similar comparisons across
species reported low correlation between these two types
of data [88–91]. Our comparison across the transcrip-
tomic and proteomics data resulted in low correlation
Table 3 Differentially abundant proteins associated with metabolism and S-adenosylmethionine-dependent methylation
Gene name Protein description FC p-value General putative function
Metabolism
Lss Lanosterol synthase 8.1 0.016 Cholesterol synthesis
Aacs* Acetoacetyl-CoA synthetase − 1.4 0.059 Ketone body utilization
Acadvl Very long-chain specific acyl-CoA dehydrogenase,
mitochondrial
1.6 0.045 Fatty acid oxidation
Ugp2# UTP-glucose-1-phosphate uridylyltransferase − 1.7 0.011 Glycogen metabolism
Acot7 Cytosolic acyl coenzyme A thioester hydrolase − 1.3 0.087 Fatty Acyl-CoA biosynthesis
Monoamine metabolism
Qdpr# Dihydropteridine reductase − 1.7 0.029 Tetrahydrobiopterin synthesis
Spr* Sepiapterin reductase − 1.5 0.083 Tetrahydrobiopterin synthesis
Maoa Amine oxidase [flavin-containing] A 1.4 0.096 Degradation of monoamines
S-adenosylmethionine-dependent methylation
Gamt Guanidinoacetate N-methyltransferase − 1.7 0.089 Creatine synthesis
Srm Spermidine synthase (SPDSY) − 1.5 0.024 Polyamine synthesis
Mthfd1l Monofunctional C1-tetrahydrofolate synthase,
mitochondrial
1.7 0.054 Folate synthesis
Significant proteins (p < 0.1) are listed by gene name (first column), followed by the full protein name (second column). For each protein, the fold change (“FC”)
and p-value is provided (third and fourth columns, respectively), along with a brief description regarding the putative function of that protein (“General Putative
Function”). Information regarding the putative function of each protein was obtained from the UniProtKB/Swiss-Prot database [131]. Gene names with an asterisk
(“*”) indicates that the corresponding gene was also identified as significantly, differentially expressed (DE) in the transcriptome by a q < 0.05, while genes with a
pound sign (“#”) indicate that gene was identified as DE in the transcriptome by a q < 0.01. Bold proteins indicate that the respective protein has been previously
identified as a RTT hit and/or MeCP2 interacting protein
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(Pearson’s R of 0.12, Fig. 4a). Within the detected gene-
protein matches, which we define as a detected gene
having a corresponding detected protein, we identified
35 significant gene-protein matches (gene expression
q < 0.05, protein expression p < 0.1) with a Pearson’s R
of 0.74 (Fig. 4b and Table 4). When we relaxed the strin-
gency in the DE gene list to p < 0.05, this value increases
to 77 significant gene-protein matches with a Pearson’s
R of 0.67 (Additional file 9).
We found 23 of the 35 significantly DE gene-
protein matches were previously identified as RTT
RNA regulatory targets (Table 4). The remaining 12
matches have not been described in previous RNA
studies (Table 4). Within the gene-protein matches
with similar regulatory patterns, Ephx2/EPHX2, Dgkg/
DGKγ, Me3/NADP-ME3, Qdpr/QDPR, Slc24a4/
SLC24A4, Ugt8a/UGT8, Aacs/AACS, Rnpep/RNPEP,
and Spr/SPR are implicated in metabolic pathways
(Table 4) [92–100]. We also found that Itih3/ITI-
HC3, Slc9a3r1/NHERF1 (both phosphorylated and
acetylated modifications), and Rnpep/RNPEP are
associated with protein scaffolding/stability (Table 4)
[99, 101–103]. Additionally, S1pr1/S1P1, Calr/CALR,
Hpcal4/HPCAL4, and Rasgrf1/RasGRF1 are implicated
in calcium-mediated processes (Table 4) [104–107].
Pathway analysis in transcriptome and proteome
implicate similar biological pathways
In an attempt to understand the underlying biology of
disrupted genes and proteins, we utilized Ingenuity®
Pathway Analysis (IPA) on the protein and RNA data
sets. For a comprehensive list of all identified pathways
in the individual transcriptome and proteome data sets
as well as the corresponding genes and proteins in each
pathway, see Additional file 10. To exemplify the diver-
sity of identified significant pathways, we highlight
functional categories that are similar or shared between
the transcriptome and proteome data sets in Figs. 5 and 6.
First, we identified pathways associated with general cellu-
lar and molecular dysfunction. This included categories
such as cell cycle, cell components/structure/general func-
tion, and lipids and metabolism (Fig. 5a-c, Add-
itional file 10). For the cell cycle category, 36% (4/11) of
the identified pathways are associated with G2 and G2/M
phase, which were found exclusively in the proteomics
data set (Fig. 5a, Additional file 10). Over 80% of the
proteins associated with these specific pathways had sig-
nificantly increased expression, suggesting hypersensitivity
and/or an accumulation of cells in the G2/M phases, a
phenomenon previously observed in RTT primary human
fibroblasts [108–110].
Within the cell components/structure/general function
category, we found a number of pathways related to cell
death, tissue/cellular morphology, and G-protein signal-
ing shared between the transcriptome and proteome
(Fig. 5b, Additional file 10). In the RTT brain, the pri-
mary morphologic change in humans is reduced brain
size [111]. Additional morphological changes include
simplified dendritic arborizations and altered spine dens-
ity and morphology [41, 112]. A recent study also identi-
fied reduced astrocyte branching and overall process
length [72]. Supporting this, pathway analysis identified
several disrupted pathways associated with tissue and
cellular morphology such as “morphology of cerebral
cortex”, “abnormal morphology of cells”, “formation of
intermediate filaments”, “quantity of plasma membrane
projections”, and “differentiation of cells” (Fig. 5b, Add-
itional file 10). Additionally, pathway analysis supports
previous findings that metabolites including glucose
[113–115], lipids/phospholipids [77, 78, 80, 115–
117], TCA cycle intermediates [115], biogenic amines
[79, 80], glutamate [80, 117], creatine [80, 85], and
steroids such as cholesterol and glucocorticoids [76,
Fig. 4 Transcriptome-proteome expression correlation in Mecp2Jae/y
cortex. a. Overall gene-protein expression correlation. Detected genes
(7026) from the RNA-Seq data set were matched against detected proteins
(4789) from the proteomics data set, resulting in a total of 3780 gene-
protein matches. Each individual gene-protein match is plotted by gene
fold change expression (x-axis, Mecp2Jae/y/WT) and its corresponding
protein fold change expression (y-axis, Mecp2Jae/y/WT). Pearson’s R reports
a correlation of 0.12. b. Significant gene and significant protein
expression correlation. Out of the 3780 detected gene-protein
matches, only 35 have both a significant gene (q < 0.05) and
corresponding significant protein (p < 0.1) match. Each match is
plotted by gene fold change expression (x-axis, Mecp2Jae/y/WT)
and its corresponding protein fold change expression (y-axis,
Mecp2Jae/y/WT). Pearson’s R reports a correlation of 0.74
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Table 4 List of significant genes with a significant protein
Gene/protein UniProt accession Gene fold change Protein fold change RTT hit? Putative function
Mecp2/MeCP2 Q9Z2D6 − 0.66 − 10.6 Yes1, 2 DNA binding protein; transcriptional
regulator
Rnpep/RNPEP* Q8VCT3 − 0.78 − 3.47 Yes2 Peptide catabolic process
Pdia4/ERp72* P08003 − 0.71 − 2.22 Yes2,3 ER protein processing
Hsph1/HSPH1 Q61699 − 0.80 − 2.13 Yes4 Protein chaperone
Rnpep/RNPEP(Ac)* Q8VCT3 − 0.78 − 2.02 Yes2 Peptide catabolic process
Aldh1a1/ALDH1A1* P24549 − 0.67 − 1.95 Yes2 Retinal dehydrogenase
Slc9a3r1/NHERF1(P)* P70441 − 0.74 − 1.79 Yes3 Scaffold protein
Ugt8a/UGT8 Q64676 − 0.79 − 1.76 — Sphingolipid metabolism
Qdpr/QDPR (or DHPR)* Q8BVI4 − 0.74 − 1.68 Yes2 Monoamine metabolism
(tetrahydrobiopterin biosynthesis)
Ugp2/UGP2* Q91ZJ5 − 0.73 − 1.67 Yes2 Glycogen synthesis
Car2/Ca2 P00920 − 0.72 − 1.61 — Reversible hydration of carbon dioxide
Grm3/mGluR3* Q9QYS2 − 0.63 − 1.6 Yes2 Protein coupled glutamate receptor
Ephx2/EPHX2* P34914 − 0.71 − 1.59 Yes2 Cholesterol synthesis
Hpcal4/HPCAL4* Q8BGZ1 − 0.69 − 1.51 Yes2,3 Calcium binding
Spr/SPR Q64105 − 0.77 − 1.47 — Monoamine metabolism
(tetrahydrobiopterin metabolic process)
Sash1/SASH1 P59808 − 0.82 − 1.44 — p38 MAPK and NIK/NF-kappaB signaling
Calr/CRT* P14211 − 0.80 − 1.43 Yes3 ER calcium-binding protein
Aacs/AACS* Q9D2R0 − 0.79 − 1.37 Yes2 Fatty acid and lipid metabolism
S1pr1/S1P1 O08530 − 0.78 − 1.28 — Cell-cell adhesion
Slc9a3r1/NHERF1(Ac)* P70441 − 0.74 − 1.24 Yes3 Scaffold protein
Nova1/NOVA1 Q9JKN6 1.26 1.28 — RNA/mRNA-binding protein
Slc24a4/Nckx4* Q8CGQ8 1.58 1.3 Yes3 K+-dependent Na+/Ca2+ exchanger
Kcnab3/Kvβ3.1 P97382 1.27 1.43 — Voltage gated K+ channel
Me3/NADP-ME3 Q8BMF3 1.28 1.46 — Mitochondrial NADP(+)-dependent
malic enzyme
Tfrc/TfR Q62351 1.32 1.48 — Cell surface receptor required for iron
uptake
Dgkg/DGKγ* Q91WG7 1.42 1.51 Yes2,3 Lipid metabolism
Prkcg/PKCγ(P)* P63318 − 0.82 1.66 Yes3 Protein kinase; LTP
Rasgrf1/RasGRF1 P27671 1.32 1.68 — Stimulates the dissociation of GDP
from RAS protein
Zmat4/ZMAT4* Q8BZ94 1.50 1.88 Yes3 DNA/RNA and p53 binding
Myo1b/Myo1b* P46735 1.32 2.02 Yes2,3 Actin binding; calmodulin binding
Fkbp5/FKBP5 Q64378 1.81 2.02 Yes2–6 Immunoregulation; protein trafficking
Wipf3/WIPF3 P0C7L0 1.23 2.26 — Cytoskeleton organization
Itih3/ITI-HC3 Q61704 1.52 2.37 — Anchor protein between hyaluronan
and matrix proteins
Gfra1/GDNFRα1* P97785 1.26 2.64 Yes2,3 RET and RAF/MAP kinase signaling
cascade
Sun2/SUN2* Q8BJS4 1.42 2.86 Yes3 Nuclear envelope protein
Significant genes were defined as having a q < 0.05, and significant proteins having a p < 0.1. Gene and protein names are provided along with the
UniProt accession number, gene and protein fold change expression values (respectively), whether the gene-protein match has been previously identified
as a RTT hit, and the respective putative function according to the UniProtKB/Swiss-Prot database [131]. DE gene-protein matches with an asterisk (*) repre-
sent genes/proteins identified in supplemental material from Chahrour et al. [4] and Veeraragavan et al. [34]. Gene-protein matches with “(Ac)” denote that
the corresponding protein had a significant acetylation PTM, and a “(P)” denotes a significant phosphorylation PTM. For the RTT hit column, a “—” indicates
the match has not been identified as a RTT hit prior to this study. Superscripts in the RTT hit column denote references for matches identified as a RTT hit
and are as follows: (1) Amir et al. [2], (2) Chahrour et al. [4], (3) Veeraragavan et al. [34], (4) Nuber et al. [21], (5) Urdinguio et al. [24], and (6) Lin et al. [33]
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78, 114, 118–120] are aberrantly regulated in RTT
(Fig. 5c, Additional file 10).
Recent interest in different neural cell types in
RTT prompted us to examine dysfunction in cell
type-specific pathways. Given the wealth of informa-
tion on neuronal dysfunction in RTT, we unsurpris-
ingly identified disrupted pathways associated with
synaptic/neurotransmission, neuronal morphology, and
development. Proteome pathway analysis also indicated
disrupted conduction and neuronal structure/organization
(Fig. 6a). These pathways and expression trends are con-
sistent with previously published work in RTT [41, 111].
Within the glial functions group, we found the majority of
pathways in both the transcriptome and proteome data
sets are associated with myelination processes, along with
astrocyte morphology, reactivation, and apoptosis (Fig. 6b).
A high number of oligodendrocyte function-based path-
ways were observed in the proteome (8/9 pathways) in
which 7 of the pathways have decreased protein expres-
sion (Fig. 6b). While the exact mechanisms of how oligo-
dendrocytes contribute to RTT pathogenesis have
received little attention, previous studies have
implicated an abnormal oligodendrocyte/myelin in-
volvement in the disease [17, 121–123]. Altogether,
the glial pathways seem to suggest abnormal glial
morphology as well as aberrant myelination functions
in RTT.
We additionally identified unique pathways associated
with inflammation/immunology and blood vessel/vascu-
lature pathways as disrupted in the transcriptome and
proteome data sets (Fig. 6c, d, respectively). Within the
inflammation/immunology category, 90% (9/10) of the
pathways had decreased gene and protein expression
(Fig. 6c). Furthermore, 7 immunology/inflammation
pathways were found to be shared in common with both
the transcriptome and proteome data sets (Fig. 6c,
Additional file 10). Indeed, our pathway analysis has
identified pathways such as “T cell development”,
“abnormal quantity of cytokine”, “recruitment of lym-
phocytes”, and “activation of lymphocytes” (Fig. 6c), in
which disruptions in T cell/T lymphocyte differentiation
and cytokine regulation have been documented in RTT
[124, 125]. These identified immunology/inflammation
pathways highlight a disrupted inflammatory component
Fig. 5 Transcriptome and proteome general cellular and molecular pathways in Mecp2Jae/y cortex. Selected biological pathways that are both
shared and unique to the transcriptome (R) and proteome (P) data sets are grouped by broad categories associated with general cellular/
molecular function: (a) cell cycle, (b) cellular components/structure/general function, and (c) lipids and metabolism. Respective pathways are
plotted by −Log10 p-value, where a value of 1.3 or greater represents a p-value of at least p < 0.05; non-significant (NS) pathways are denoted in
white. The direction of gene (gray bars) and/or protein (black bars) expression changes associated with each respective pathway are represented
as a percent expression to the right of the heat map, where a value greater than 0 indicates increased expression and a value less than 0 indi-
cates decreased expression. The percent expression was calculated by taking the number of genes/proteins with significant increased or de-
creased expression divided by the total sum of significant genes/proteins assigned to the respective pathway. Note in part B, the abbreviation
“AC” in the “G-protein signaling, AC inhibiting pathway” stands for “adenylate cyclase.” For a comprehensive list of all pathways and associated sig-
nificant genes/proteins identified in both the transcriptome and proteome data sets, see Additional file 10
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in RTT, a topic that has received considerable recent
attention [124, 125].
Finally, we observed a number of pathways associated
with blood cells such as “production of blood cells”, “ex-
pansion of blood cells”, “recruitment of blood cells”, and
“elimination of blood cells” (Fig. 6d). This is particularly
interesting as platelet defects have been observed in RTT
patients with FOXG1 mutations [126]. While few studies
have examined general vasculature in RTT, defects in vas-
cular function have been previously observed [127]. The
above identified pathways suggest a dysregulated function
of the vasculature, and perhaps an increased risk of blood-
brain barrier breakdown (a pathway also identified in the
proteomics data, Fig. 6d), in RTT symptomatic WCX.
Discussion
To provide a more complete understanding of how
MeCP2 deficiency contributes to cellular and molecular
dysfunction, we performed comparative analyses
between global gene and protein expression in Mecp2-
deficient mice. Comparing the RNA-Seq data to a
publicly available database of cell type-specific gene ex-
pression [69], we observed more than 30% of the identi-
fied DE genes could be ascribed to specific cell
populations. We confirmed previous reports [30, 32] indi-
cating long genes were over-expressed in the neuronal
population, a pattern that was also observed in oligoden-
drocytic cells. In contrast, astrocytic, microglial, and
endothelial genes were decreased regardless of gene size.
Fig. 6 Transcriptome and proteome cell type-specific pathways in Mecp2Jae/y cortex. Selected biological pathways that are both shared and
unique to the transcriptome (R) and proteome (P) data sets are grouped by broad categories associated with CNS and general cell type specific function:
(a) neuronal functions, (b) glial functions, (c) immunological/inflammation functions, and (d) blood/blood vessel/vasculature. Respective pathways are plot-
ted by −Log10 p-value, where a value of 1.3 or greater represents a p-value of at least p < 0.05; non-significant (NS) pathways are denoted in white. The dir-
ection of gene (gray bars) and/or protein (black bars) expression changes associated with each respective pathway are represented as a percent expression
to the right of the heat map, where a value greater than 0 indicates increased expression and a value less than 0 indicates decreased expression. The per-
cent expression was calculated as described in Fig. 5. Note in part B, the abbreviation “EAE” stands for “experimental autoimmune encephalomyelitis”; in
part C, the abbreviation “APCs” in the pathways “Immune response of APCs” and “Cell movement of APCs” stands for “antigen presenting cells.” For a compre-
hensive list of all pathways and associated significant genes/proteins identified in both the transcriptome and proteome data sets, see Additional file 10
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Our proteomics data indicate hundreds of novel protein
targets, including proteins involved in proteostasis, metab-
olism, S-adenosylmethionine-dependent methylation, and
an altered stress response. A comparison between RNA-
Seq and proteomics data indicates relatively low correl-
ation between the two data sets. However, 35 significant
gene-protein target hits were found common to both data
sets. Together, these data may serve as a resource for
those interested in cellular dysfunction in Rett syndrome.
Why the proteome?
Much of our understanding of MeCP2 function is de-
rived from transcriptomic studies, with the general
assumption that alterations in the transcriptome correl-
ate with proteomic changes. Challenging this central
dogma, recent studies indicate that RNA-protein expres-
sion correlations are low even when comparing the same
tissue samples [88–91]. There are a number of reasons
given for the observed discrepancies, including differ-
ences in stability and lifetime of the two types of mole-
cules, posttranscriptional and posttranslational
modifications, and protein turnover [90, 91]. These
changes are likely to be exacerbated in a disease state,
particularly a disease such as RTT where data indicates
RNA metabolism and proteostasis are disrupted
(Table 2). Thus, the primary benefit of performing a dir-
ect comparison between transcriptomic and proteomic
data is the ability to complement the knowledge gained
from each of these omics technologies, providing a more
holistic understanding of the interplay between gene and
protein expression regulation. The benefits of such com-
parisons are reflected in our pathway analyses, where
“neuronal transmission”, “synaptic transmission”,
“excitation of neurons”, “morphology of neurons”, and
“development of neurons” pathways are unique to the
transcriptome data set. Supplementing these transcrip-
tomic pathways, pathways identified using the proteome
data indicated “abnormal conduction”, “damage of
synapses”, “atrophy of axons”, and “organization of
neurofilaments” as disrupted. These findings indicate
that evaluating data obtained from multiple omics
platforms provide a more complete understanding of
disease biology.
While the current study has only examined transcrip-
tomic and proteomic expression changes in symptomatic
Mecp2-deficient male mice, we recognize that utilization
of a heterozygous female Mecp2-deficient mouse model
is more clinically relevant. To date, the majority of tran-
scriptomic and proteomic studies have been performed
in male animal models. Therefore, we chose to use
symptomatic Mecp2-deficient male mice for comparison
with existing data in the RTT field. Future studies should
be directed toward understanding proteomic and
transcriptomic changes occurring in the same RTT fe-
male mouse model and tissue region.
Cell type-specific gene and protein expression
Neurons
MeCP2 is most highly expressed in neurons and loss of
MeCP2 contributes to neuronal cell dysfunction [11, 12].
We identified 2 neuronal-enriched hits Dgkg/DGKγ and
Zmat4/ZMAT4. Studies have shown loss of DGKγ is as-
sociated with decreased cell density and increased cell
soma size [128]. It is possible that upregulation of DGKγ
in our data may be compensating for the increased neur-
onal packing density and decreased soma size observed
in RTT [12, 40, 41, 111, 129]. Zmat4 localizes within
cerebellar cortical and granule cell layer inhibitory inter-
neurons [130]. UniProtKB biological and molecular gene
ontology terms for Zmat4 suggest that it may be in-
volved in DNA/RNA binding [131].
Pathways identified from the transcriptome and
proteome data sets relating to neuronal and synaptic
transmission, damaged synapses, and abnormal neuronal
morphology have been previously described [41, 111]. For
example, the “damage of synapse” pathway was identified
exclusively in the proteome, in which the proteins PrPC
(Prnp) and PLAA (Plaa) were differentially abundant in
this pathway. PrPC plays a role in mediating synaptic
transmission and long-term potentiation [132]. PLAA is
an ubiquitin-binding protein, in which reduced function
has led to a disruption in synaptic structure and vesicle
recycling in neurons [133]. Additionally, the autism candi-
date gene Rab11fip5 was upregulated in our proteome
data and plays a role in recycling endosome protein traf-
ficking and neurotransmitter release [134]. Defects in
these proteins could affect how neurotransmitters like
BDNF, a well-known MeCP2 target reduced in RTT [41,
134, 135], get internalized and processed.
Astrocytes
Astrocyte MeCP2 deficiency may contribute to RTT
symptoms [14, 15, 18]. Astrocytic mGluR3, a metabotro-
pic receptor known to mediate calcium signals in hippo-
campal astrocytes [136], was downregulated in our data
sets. Sphingosine 1-phosphate receptor 1 (S1pr1/S1P1),
similarly related to calcium signaling in astrocytes, was
also downregulated. While astrocytic calcium signaling
has not been directly investigated within the astrocyte
RTT field, astrocyte dysregulated calcium signaling has
been implicated in related disorders such as Hunting-
ton’s disease [137] and epilepsy [138].
Previous work has implicated aberrant astrocyte
microtubule dynamics [139, 140] and decreased
astrocyte morphological complexity [72] in RTT. The
significant gene-protein hit Slc9a3r1/NHERF1 is associ-
ated with cellular structure/morphology, localizes in the
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plasma membrane of astrocytes [141, 142], and can
transport/anchor G-protein coupled receptors (GPCRs)
and ion channels/exchangers to the plasma membrane
[143]. We found known protein-binding partners Moe-
sin, Merlin, and PTEN [103, 142, 144], the astrocytic
glutamate transporter GLAST [141], and astrocytic-
specific GPCRs mGluR3 and S1P1 are disrupted in the
proteomic or transcriptomic data sets. It is therefore
possible that aberrant changes and interactions between
these proteins and NHERF1 could contribute to the ob-
served astrocytic morphological defects in RTT [72].
Finally, pathway analysis of astrocytes confirmed “re-
activation of astrocytes” and “morphology of neuroglia”
pathways were disrupted. Unlike the vast majority of
brain pathological states, our data sets indicated that
rather than upregulation of reactive astrocyte markers,
markers associated with reactive gliosis (Gfap, Gap43,
Vim, HSPB1, and ANXA3) were significantly decreased
in the RNA-Seq and proteomics data. This suggests that
there is a decrease in astrocytic reactivation in RTT,
rather than a typical reactive gliosis as seen in most
neurological diseases.
Microglia
While none of our 35 significant gene-protein matches
were considered microglial-enriched, we did identify 10
DE genes and 4 altered proteins (Additional file 3).
C1qa, Tyrobp, and C1QB (all decreased expression) were
identified as differentially expressed in RTT patients and
are associated with the C1Q complement cascade [33].
Other genes associated with the C1Q complement
cascade were also significantly decreased in our tran-
scriptomic data (Pdgfra and Dcn, Additional file 1).
Genetic manipulation of C1Q leads to aberrant pruning
by microglia, and excessive engulfment of presynaptic
inputs by microglia has been reported in Mecp2-null
mice [145]. It is also possible that fewer microglia exist
in the RTT brain. This has been suggested by Cronk et
al. [146] who found microglia are activated and then lost
during RTT disease progression. Because our studies
were not carried out during the critical developmental
period of synaptic refinement, it is unclear how these
changes might contribute to altered synapse numbers re-
ported in the RTT brain [147].
Oligodendrocytes and their progenitors
One of the shared pathways disrupted in the transcrip-
tome and proteome, “abnormal morphology of oligoden-
drocytes”, relates to abnormal oligodendrocytes. Many
significant glial pathways per data set also related to ab-
normal migration and myelination/demyelination of
oligodendrocytes. In support of these findings, we found
a number of proteins associated with myelination that
were differentially abundant in our proteomics data
(Additional files 3 and 6). Nguyen and colleagues identi-
fied MBP and PLP disruptions in Mecp2-deficient
oligodendrocyte lineage cells [17]. Yet, MeCP2 rescue
experiments in oligodendrocytes only partially restored
MBP expression while PLP remained abnormally
expressed, suggesting other cell types may have a non-
cell-autonomous effect on oligodendrocyte lineage cells
in RTT [17].
Furthermore, 3 of the 12 novel significant gene-
protein hits identified in our data are oligodendrocyte-
enriched: Me3/NADP-ME3, Ugt8a/UGT8, and Gfra1/
GDNFRα1, in which the former two hits have been im-
plicated in metabolism [94, 97]. Additionally, Ugt8a
knockout mice present with tremors and ataxia [148,
149], which are common symptoms reported in RTT
[135]. GDNFRα1 is a candidate for Hirschsprung’s
disease [150], a congenital disorder resulting in loss of
nerve cells within the large intestine, and causes consti-
pation, a common symptom of RTT patients [151, 152].
Additionally, the disease/biological function pathway
“Hirschsprung’s disease” was also identified in our tran-
scriptome pathway analyses (Additional file 10).
Endothelial cells
In this study, we identified a novel and previously identi-
fied RTT endothelial-enriched hits where the gene and
protein were altered: Tfrc/TfR and Myo1b/Myo1b, re-
spectively. TfR is a transferrin receptor localized on the
plasma membrane of brain capillary endothelial cells
and plays a role in transferrin-bound iron transport
across the blood-brain barrier (reviewed in [153]). A mu-
tation in WDR45 has been demonstrated in cases of
atypical RTT [154, 155], leading to brain iron accumula-
tion [156]. Additionally, one of the pathways identified
in the pathway analysis was “permeability of the blood
brain barrier” as well as other blood/vasculature path-
ways (Additional file 10). A more recent study has found
that peripheral blood mononuclear cells have an abnor-
mal cellular morphology as well as altered chemokine
and cytokine profiles in RTT patients [125]. Addition-
ally, another group has examined mesenteric vessel
resistance in RTT mice and found that decreased
levels of nitric oxide contribute to endothelial dys-
function [127].
Conclusions
Overall, we have provided the first comprehensive tran-
scriptome and proteome data set comparison for any
RTT model to date, with the goal of providing a more
comprehensive view into the biological dysfunction
associated with MeCP2 deficiency. Through the inte-
gration of these unbiased multi-omics approaches,
hundreds of novel genes, proteins, and pathways were
identified. Our data indicate that future studies
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performed in discrete cell populations may provide
additional insight into disease biology. By providing
this valuable resource, two important types of infor-
mation are now available for the RTT community: (1)
novel gene/protein hits associated with pathways cur-
rently under active investigation and (2) new genes,
proteins, and pathways that have not been described
in RTT and available for open investigation. The re-
inforcing nature of a combined transcriptomic and
proteomic comparison could potentially shed light
into future novel therapeutic targets for RTT patients.
Additional files
Additional file 1: Complete list of significant, differentially expressed
(DE) genes identified in Mecp2Jae/y cortex. NCBI gene names with WT and
Mecp2Jae/y FPKM values, Log2 fold change expression, and q-value (FDR)
are provided for each identified DE gene. File format: Microsoft Excel
spreadsheet. (XLS 84 kb)
Additional file 2: List of significant genes (p < 0.05) identified as RTT hits
along with references. Information on WT and Mecp2Jae/y FPKM values, Log2
fold change expression, p-value and q-value (FDR) are provided per
respective gene (based on NCBI designation). The directions of expression
for the RTT hits observed in previous studies (with references) are also
provided. File format: Microsoft Excel spreadsheet. (XLS 34 kb)
Additional file 3: List of significant genes and proteins that are CNS cell
type-specific. Each individual tab represents one expression data set, with
each containing respective gene/protein name and identity, FPKM or
relative peptide abundance, fold change expression, estimated size, p-,
and/or q-value (FDR), and which CNS cell population each gene/protein
belongs to. File format: Microsoft Excel spreadsheet. (XLS 213 kb)
Additional file 4: CNS cell type-specific genes from Zhang et al.’s study
compared to the Sharma et al. study. Significant DE genes (DEG) identified
as cell type-specific from the Zhang et al. study [69] were compared to CNS
cell type-enriched proteins identified from the Sharma et al. study [60]. Each
tab contains information on one specific CNS cell type. Within each tab,
information is broken up by 3 parts: part 1 (highlighted in blue)—gene
expression information on genes identified in this study, including WT and
Mecp2Jae/y FPKM values, Log2 fold change expression, and q-value (FDR); part
2 (highlighted in light orange)—gene identified as CNS cell type-specific in
the Zhang et al. study [69] along with the respective gene’s fold change
enrichment in the identified cell type relative to all other CNS cell types; and
part 3 (highlighted in purple)—gene/protein identified as CNS cell type-
specific in the Sharma et al. study [60] along with the respective gene’s fold
change enrichment (Log2 fold expression and Log2 LFQ intensity) in
the identified cell type relative to all other CNS cell types, −Log10 p-
value, standard deviation in LFQ intensity, and UniProt accession iden-
tity (major protein IDs). For oligodendrocytic-enriched genes, genes enriched
in oligodendrocyte precursor cells (OPC), newly formed oligodendrocytes, and
myelinating oligodendrocytes from the Zhang et al. study [69] were combined
under the broad category “oligodendrocyte-enriched.” For endothelial-
enriched genes, only genes identified as endothelial-enriched genes from the
Zhang et al. study [69] are provided since the Sharma et al. study [60] did not
examine endothelial cells. File format: Microsoft Excel spreadsheet. (XLS 71 kb)
Additional file 5: Gene size and fold change expression breakdown for
CNS cell type-specific DE genes. Significant DE genes with CNS cell type-
specific designations were broken down into 4 categories—(1) decreased
expression, gene size < 100 kb (blue); (2) decreased expression, gene size
> 100 kb (light orange); (3) increased expression, gene size < 100 kb
(purple); and (4) increased expression, gene size > 100 kb (red).
Within each category, DE genes are organized by their respective
CNS cell type-specific distribution. The exact Log2 fold change and
gene size (kb) values are listed for each DE gene. File format:
Microsoft Excel spreadsheet. (XLS 66 kb)
Additional file 6: Complete list of significant, differentially abundant
proteins identified in Mecp2Jae/y cortex. List of 465 significant proteins/
PTMs with UniProt accession identity, number (#) of peptides quantified,
WT and Mecp2Jae/y relative abundances, fold change expression (represented
as Mecp2Jae/y relative abundance/WT relative abundance), p-value, subcellular
location, putative function, and hyperlink are provided. File format: Microsoft
Excel spreadsheet. (XLS 302 kb)
Additional file 7: Western blot and mass spectrometry chromatogram
validation of the selected, significantly expressed protein hits. A. Western
blot quantification of 7 proteins selected for validation. All 7 proteins
(x-axis) were quantified relative to GAPDH (y-axis). Gray bars indicate WT
expression (n = 4), and turquoise bars indicate Mecp2Jae/y expression
(n = 4–5). Asterisks indicate statistically significant genotype expression
differences (*p < 0.05). B. Representative Western blot images for selected
proteins. Due to space constraints, only Western blot images for 4 out of
the 7 proteins are shown. GAPDH was used as the loading control and is
shown for each respective group of blots. For the mGluR3 blot, the
arrows denote that 2 bands are detected, where the 100-kDa band
represents the expected molecular weight (denoted with “*”). For the
MeCP2 blot, the top arrow denotes the expected molecular weight, while
the bottom arrow indicates the expected GAPDH molecular weight. C.
Representative mass spectrometry chromatograms for selected validated
proteins. Due to space constraints, only 4 out of the 7 chromatograms
for proteins validated by Western blot analysis are shown. The top row
represents chromatograms from WT cortex, while the bottom row
represents chromatograms from Mecp2Jae/y cortex. Each chromatogram
shows the relative intensity of the respective protein’s peptide concentra-
tion (y-axis, in units of 103) in relation to its elution time (x-axis, in units of
minutes) from the mass spectrometer for 1 biological replicate (for each
genotype, the most representative chromatogram out of the 4 biological
replicates was chosen). For the CIRBP chromatograms, arrows denote the
peaks corresponding specifically to the CIRBP protein. Chromatograms for
the remaining 3 proteins (HSPH1, RNPEP, and QDPR) showed similar and
notable decreases in peptide changes in Mecp2Jae/y cortex (data not
shown). File format: TIFF image. (TIFF 1874 kb)
Additional file 8: List of significant proteins/PTMs (p < 0.1) identified as
RTT hits along with references. Information on WT and Mecp2Jae/y relative
abundance values, fold change expression, and p-value are provided
per respective protein/PTM. RTT hits identified from proteomics-based
studies are highlighted in yellow. File format: Microsoft Excel spread-
sheet. (XLS 33 kb)
Additional file 9: List of 77 gene-protein matches (gene expression
p < 0.05, protein expression p < 0.1). Information on WT and Mecp2Jae/y
FPKM/relative abundance values, UniProt accession identifier, fold change
expression, p-, and q-value, CNS cell type-specific identity, and any
relevant RTT hit references is provided for each gene-protein match.
File format: Microsoft Excel spreadsheet. (XLS 55 kb)
Additional file 10: List of all pathways identified in proteomics and
RNA-Seq data sets. Pathways identified in either the proteomics or RNA-
Seq data sets are provided (“Diseases and Biological Functions”) along
with the −Log10 p-value (i.e., −Log10 p > 1.3 is the equivalent of p < 0.05)
associated with each pathway per respective data set. In addition, the
number and names of the genes/proteins identified with each respective
pathway are listed. File format: Microsoft Excel spreadsheet. (XLS 179 kb)
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